Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Intensive Case Management for Substance Use Disorders (RCT) (ICM)

13. november 2026 opdateret af: Psychiatric Services Aargau AG

Intensive Case Management for Patients With Substance Use Disorders and Complex Psychosocial Needs: A Randomized Controlled Trial

This study aims to assess the effectiveness of Intensive Case Management (ICM) compared to TAU. Economically, this study could contribute to more cost-effective treatments, since relatively expensive inpatient care could be relieved of patients not benefiting from inpatient care, and those patients would receive a more adequate and effective treatment. Our first goal is to evaluate the effectivenessof ICM as a treatment for people with SUDs in the canton of Aargau compared to TAU. To assess the effectiveness, the outcome measured will be the RICID and the NOIA. Furthermore, the increase in Quality of Life and Social Integration with appropriate Questionnaires of Patients in ICM is compared to Patients in TAU. The second goal of this study is to evaluate the cost-effectiveness of ICM for the aforementioned patients compared to TAU.

Case Management, especially for people with multiple and complex needs, is an intervention designed to enhance coordination and continuity of support and care (Vanderplasschen et al. 2019). Also, for people with high levels of disability due to mental illness, ICM is widely claimed to be an evidence-based and cost-effective program (King, 2006). Furthermore, key ICM components, linkage and retention, seem to show the largest effect sizes (SMD = 0.33, 95% CI 0.18-0.48) in ICM. Linkage and retention are necessary prerequisites that keep patients with SUDs in contact with health services (Vanderplasschen et al., 2019). Although evidence across all outcome measures, according to the same author, is significant and positive, but small (SMD = 0.18, 95% CI [0.07-0.28]). There is mixed evidence in outcomes such as health outcomes (SMD = -0.16, 95%CI [-0.40, 0.08]), social functioning (SMD = 0.14, 95% CI [-0.01, 0.28]) or reduced substance use (SMD = 0.10, 95% CI [-0.02, 0.21]).

Moreover, ICM and closely related models (i.e., Assertive Community Treatment, ACT) show a Reduction in Cumulative Inpatient Days (RICID) and a reduction in inpatient admissions (Dietrich et al., 2017; Burns et al., 2007). This is a common outcome in ICM literature and is also a measure for reductions in healthcare costs, since inpatient treatments are bound to high costs.

In this study, there are mainly four groups of patients with SUDs that, despite previous or present linkages to health services, do need further or a different kind of treatment. Those patients are:

  • People with low treatment satisfaction and high usage of health and social services: These patients, despite their previous treatments and social connections, do not improve sufficiently and continue to utilize healthcare services.
  • people that already are in complex helping systems and make use of a high number of treatments but show a high need for coordination to be effective
  • patients with dual diagnosis, with SUD being one of those in combination with, e.g., schizophrenia, personality disorders and anxiety disorders and would need intense and continuous care.
  • people that, due to their clinical picture or other difficulties in life, do not have access to existing treatments (anymore) and fall through the social network. It includes people without permanent addresses, people with precarious housing conditions or socially isolated people, independent of their employment status.

Sex and gender will be treated as potential covariates and will be considered in the analysis.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

180

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Canton of Aargau
      • Windisch, Canton of Aargau, Schweiz, 5210
        • Rekruttering
        • PDAG
        • Kontakt:
        • Ledende efterforsker:
          • Johannes Senesi, Msc

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 64 år (Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • 4 or more inpatient admissions in the last 24 months
  • Diangosed SUD
  • Residence or temporary stay in the canton of Aargau

Exclusion Criteria:

  • any emergency situation requiring psychiatric or hospital admissions
  • inability to give informed consent
  • acute, unstable psychotic symptoms
  • acute risk of harm to self or others
  • insufficient german language skills

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Sundhedstjenesteforskning
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Experimental

receives ICM immediately

Intensive Case Management for People with SUDs and complex psychosocial needs is an outreach-based intervention aimed at linking participants to health services and coordinating them. Additionally, two focus points are implemented to increase adherence and engagement:

  1. Intensive crisis intervention: Offering immediate, flexible support in acute crises, preventing escalations early and strengthening the stability of patients.
  2. Relationship continuity: Establishing an empathetic & constant presence, breaking down barriers, creating a trustful, stable relationship.
Aktiv komparator: Waiting List

Same as Experimental, only with 6-Month TAU-Waiting List before ICM

TAU will take place for 6 months before starting with ICM

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Inpatient Admissions (Health Service utilisation)
Tidsramme: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Number of Inpatient Admissions into psychiatric care. This measure only reflects the presence of patients on the ward and is strenghtend by Continuity of Care, Linking and Retention.

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
Number of Inpatient Days (Health Service utilisation)
Tidsramme: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Number of Inpatient Days in psychiatric care. This measure only reflects the presence of patients on the ward and is strenghtend by Continuity of Care, Linking and Retention.

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
WHOQoL-BREF
Tidsramme: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Quality of Life

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
SFQ
Tidsramme: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Social Functioning Questionnaire

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
ASSIST
Tidsramme: 6 Months (exploratory), 24 months (exploratory)

Substance use characteristics

6 Months (exploratory), 24 months (exploratory)
Continuity of Care (Brice-Boxerman)
Tidsramme: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Continuity of Care describes timeframes of the health services used outside the ward.

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
Linking
Tidsramme: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Linking describes the successful referral to health services not captured by the primary endpoint (meaning, outside the ward) and is the central mechanism of this Intensive Case Management.

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
Retention
Tidsramme: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Retention describes the voluntary staying of patients in the ICM treatment

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
BSCL
Tidsramme: 6 Months (exploratory), 24 months (exploratory)

Brief Symptoms Checklist, measuring the most common somatic and psychological symptoms found in psychiatric care

6 Months (exploratory), 24 months (exploratory)
EQ-5D-5L
Tidsramme: 6 Months (exploratory), 24 months (exploratory)

EuroQOL Quality of Life questionnaire for assessing cost-effectiveness (Incremental cost-effectiveness ratio, ICER)

6 Months (exploratory), 24 months (exploratory)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

4. juli 2026

Primær færdiggørelse (Anslået)

1. juli 2029

Studieafslutning (Anslået)

1. juli 2029

Datoer for studieregistrering

Først indsendt

13. november 2026

Først indsendt, der opfyldte QC-kriterier

13. november 2026

Først opslået (Faktiske)

19. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

19. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

13. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • PDAG-ICM
  • HumRes68440 (Anden identifikator: Human Research Switzerland (HumRes))

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner